Anterior Juxtascleral Delivery of Anecortave Acetate in Eyes with Primary Open-Angle Glaucoma: A Pilot Investigation

American Journal of Ophthalmology

Volumn 147, Issue 1, 2009, Pages

  Robin, Alan L ^a,b   Clark, Abbot F ^c   Covert, David W ^c   Krueger, Scott ^c   Bergamini, Michael V W ^c   Landry, Theresa A ^c   Dickerson Jr , Jaime E ^c   Scheib, Sally A ^c   Realini, Tony ^d   Defaller, Joseph M ^c   Cagle, Gerald D ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c ALCON RESEARCH LTD   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG TOLERABILITY; FEMALE; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

EID: 57549112594     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.07.039     Document Type: Article

References (31)

1. Reardon G., Schwartz G.F., and Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 13 (2003) S44-S52
2. Quigley H.A., Friedman D.S., and Hahn S.R. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 114 (2007) 1599-1606
3. Robin A.L., and Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?. Ophthalmology 112 (2005) 863-868
4. Tsai J.C., McClure C.A., Ramos S.E., Schlundt D.G., and Pichert J.W. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 12 (2003) 393-398
5. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713
6. American Academy of Ophthalmology. Primary open-angle glaucoma: Preferred Practice Pattern (2005), American Academy of Ophthalmology, San Francisco, California
7. O'Connor D.J., Martone J.F., and Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 133 (2002) 836-837
8. Higginbotham E.J., Feldman R., Stiles M., and Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 120 (2002) 915-922
9. Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 240 (2002) 893-899
10. Feldman R.M., Tanna A.P., Gross R.L., et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology 114 (2007) 1248-1254
11. Young T.L., Higginbotham E.J., Zou X.L., and Farber M.D. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology 97 (1990) 1423-1427
12. Covert D., Robin A.L., and Novack G.D. Systemic medications and glaucoma patients. Ophthalmology 112 (2005) 1849
13. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 110 (2003) 2372-2383 discussion 2384-2385
14. Clark A.F. AL-3789: a novel ophthalmic angiostatic steroid. Exp Opin Invest Drugs 6 (1997) 1867-1877
15. McNatt L.G., Weimer L., Yanni J., and Clark A.F. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 15 (1999) 413-423
16. Penn J.S., Rajaratnam V.S., Collier R.J., and Clark A.F. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42 (2001) 283-290
17. DeFaller J.M., and Clark A.F. A new pharmacologic treatment for angiogenesis. In: Taylor H.R. (Ed). Pterygium (2000), Kugler Publications, The Hague, The Netherlands 159-181
18. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration: interim (month 6) analysis of clinical safety and efficacy. Retina 23 (2003) 14-23
19. Distelhorst J.S., and Hughes G.M. Open-angle glaucoma. Am Fam Physician 67 (2003) 1937-1944
20. Haymes S.A., Leblanc R.P., Nicolela M.T., Chiasson L.A., and Chauhan B.C. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci 48 (2007) 1149-1155
21. Realini T., and Fechtner R.D. 56,000 ways to treat glaucoma. Ophthalmology 109 (2002) 1955-1956
22. Olthoff C.M., Schouten J.S., van de Borne B.W., and Webers C.A. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 112 (2005) 953-961
23. Konstas A.G., Maskaleris G., Gratsonidis S., and Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye 14 (2000) 752-756
24. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133 (2000) 21-30
25. Martin D.F., Parks D.J., Mellow S.D., et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 112 (1994) 1531-1539
26. Kuppermann B.D., Blumenkranz M.S., Haller J.A., et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125 (2007) 309-317
27. Jaffe G.J., Martin D., Callanan D., Pearson P.A., Levy B., and Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113 (2006) 1020-1027
28. Clark A.F. Steroids, ocular hypertension, and glaucoma. J Glaucoma 4 (1995) 354-369
29. Clark A.F., Wilson K., deKater A.W., Allingham R.R., and McCartney M.D. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci 36 (1995) 478-489
30. Gottanka J., Chan D., Eichhorn M., Lutjen-Drecoll E., and Ethier C.R. Effects of TGF-beta2 in persued human eyes. Invest Ophthalmol Vis Sci 45 (2004) 153-158
31. Fleenor D.L., Shepard A.R., Hellberg P.E., Jacobson N., Pang I.H., and Clark A.F. TGF-beta2-induced changes in the human trabecular meshwork: implications for glaucoma. Invest Ophthalmol Vis Sci 47 (2006) 226-234